FDA was the subject of widespread controversy this week—but not for the usual reasons. The agency launched a "wide-ranging surveillance operation against a group of its own scientists used as an enemies list of sorts as it secretly captured thousands of e-mails that the disgruntled scientists sent privately to members of Congress, lawyers, labor officials, journalists, and even President Obama," according to the New York Times. Also this week, St. Jude surprised analysts with relatively flat Q2 results despite a slew of recall-related and media woes. Read about these and other top stories of the week in our roundup below.

• Vast FDA Effort Tracked E-Mails of Its Scientists (New York Times)
• Scientist Behind FDA Flap Sued Prior Employers (Wall Street Journal)
• St. Jude CRM Stays Strong Despite Endless Controversy, Scrutiny, and Bad Press (MPMN)
• St. Jude Medical CEO: The CRM Market Hasn't Hit Bottom Yet (MassDevice)
• The U.S. Medical Device Industry in 2012: Challenges at Home and Abroad (MD+DI)
• Has J&J Grown Too Big? (Qmed)
• FDA Has Device Makers Looking Outside U.S. (OC Register)
• Are Politicians the Biggest Enemy to Medtech Innovation? (MD+DI)
• Telemedicine, Reducing Readmissions Among Independence Blue Cross Innovation Finalists (MedCity News)